# NeuroAge Therapeutics

> NeuroAge Therapeutics is a San Francisco tech-bio company that measures how old your brain actually is - and tries to make it younger. Founded in 2022 by physician-scientist Dr. Christin Glorioso, the company's flagship NeuroAge Test blends brain MRI, cognitive games, proprietary RNA blood biomarkers, and genetic screening into a single 'brain age' score that aims to flag dementia risk up to 30 years before symptoms appear. The longer-term goal is bolder: small-molecule drugs that reprogram aging neurons back toward a younger state.

- **Founded:** 2022
- **Headquarters:** San Francisco, California, United States
- **Founders:** Christin Glorioso (CEO & Co-Founder (MD, PhD))
- **Team size:** ~14-17 employees (core team plus interns and a ~6-member advisory board)
- **Products:** NeuroAge Test / Test Ultra, NeuroAge Blood Test, Brain MRI, Genetic Resilience Analysis, AD-Detect Blood Test
- **Notable:** Winner, US National Institute on Aging Startup Challenge 2022, Recipient of a $250,000 ADDF Diagnostics Accelerator grant, Recipient of an Illumina sequencing grant

## Products & services

- **NeuroAge Test / Test Ultra** — Comprehensive multi-modal brain-age workup combining MRI, genetics, RNA blood test, AD-Detect, NeuroGames and expert interpretation into a single brain-age score tracked over time (approx. $3,895).
- **NeuroAge Blood Test** — Proprietary RNA biomarker test measuring ~52 gene RNA levels in blood that are predictive of brain aging (approx. $899).
- **Brain MRI** — Volumetric brain imaging with a 3D dashboard; approx. $1,398, or $399 if uploading an existing scan.
- **Genetic Resilience Analysis** — Whole-genome sequencing screening 300+ neurodegenerative disease risk markers (approx. $249-$799).
- **AD-Detect Blood Test** — Alzheimer's biomarker blood test (approx. $799).
- **NeuroGames** — AI-driven cognitive testing and brain-training platform (approx. $9.99/month).
- **Coaching Program** — One-on-one brain-health coaching sessions with Dr. Glorioso (approx. $280/session).
- **Reprogramming Therapeutics (in development)** — Longer-term pipeline of small-molecule drugs designed to reprogram aging neurons into a younger, healthier state.

## Achievements

- Winner, US National Institute on Aging Startup Challenge 2022
- Recipient of a $250,000 ADDF Diagnostics Accelerator grant
- Recipient of an Illumina sequencing grant
- Winner of an MBC BioLabs Golden Ticket
- Named one of the top 10 companies to watch in 2023 by Life Science Nation
- Models validated on brain data from 500,000+ individuals
- Launched the NeuroAge Test predicting dementia risk up to 30 years before symptoms (announced Nov 2024)

## Latest updates

- **2026-02** — Reported latest funding activity (Seed stage), with total funding around $430K.
- **2024-11** — Unveiled the NeuroAge Test, which predicts dementia risk up to 30 years before symptoms appear.
- **2024** — Awarded $250,000 from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator.

## Links

- Website: https://neuroagetx.com
- LinkedIn: https://www.linkedin.com/company/neuroage-therapeutics
- Twitter/X: https://x.com/NeuroAgeTX
- YouTube: https://www.youtube.com/@NeuroAgeTherapeutics-gp3ug
- Instagram: https://www.instagram.com/neuroage_therapeutics/
- Facebook: https://facebook.com/share/18kkp49YoA/

---

Profile page: https://yespress.io/neuroage-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-03